OA10.03 Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up
| Autor: | Sands, J., Cho, B.C., Ahn, M.-J., Reck, M., Bustamante-Alvarez, J., Hummel, H.-D., Akamatsu, H., Johnson, M.L., Felip, E., Handzhiev, S., Korantzis, I., Izumi, H., Dingemans, A.-M., Blackhall, F., Owonikoko, T.K., Wolf, J., Ramalingam, S.S., Borghaei, H., Huang, S., Jiang, T., Anderson, E.S., Martinez, P., Hamidi, A., Mukherjee, S., Paz-Ares, L. |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology October 2024 19(10) Supplement:S30-S31 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|